Embecta (NASDAQ:EMBC) Lowered to “Buy” Rating by Wall Street Zen

Wall Street Zen cut shares of Embecta (NASDAQ:EMBC) from a strong-buy rating to a buy rating in a research note issued to investors on Saturday.

EMBC has been the topic of several other research reports. Weiss Ratings reissued a “hold (c-)” rating on shares of Embecta in a report on Wednesday, January 21st. BTIG Research reiterated a “buy” rating and issued a $25.00 price target on shares of Embecta in a research note on Friday. One analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $18.50.

Embecta Stock Up 3.7%

NASDAQ:EMBC opened at $10.86 on Friday. The business’s 50-day simple moving average is $11.76 and its two-hundred day simple moving average is $12.97. Embecta has a 52 week low of $9.20 and a 52 week high of $18.07. The stock has a market cap of $643.02 million, a PE ratio of 4.58 and a beta of 1.11.

Embecta (NASDAQ:EMBC) last released its quarterly earnings data on Thursday, February 5th. The company reported $0.71 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.04. The firm had revenue of $261.20 million during the quarter, compared to analyst estimates of $258.07 million. Embecta had a negative return on equity of 26.66% and a net margin of 12.92%.The business’s quarterly revenue was down .3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.65 earnings per share. Embecta has set its FY 2026 guidance at 2.800-3.00 EPS. Sell-side analysts anticipate that Embecta will post 2.85 earnings per share for the current fiscal year.

Embecta Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 17th. Investors of record on Friday, February 27th will be given a $0.15 dividend. The ex-dividend date is Friday, February 27th. This represents a $0.60 annualized dividend and a yield of 5.5%. Embecta’s dividend payout ratio (DPR) is currently 25.32%.

Institutional Investors Weigh In On Embecta

Several institutional investors have recently modified their holdings of EMBC. LSV Asset Management increased its position in shares of Embecta by 92.5% during the 4th quarter. LSV Asset Management now owns 552,582 shares of the company’s stock valued at $6,565,000 after purchasing an additional 265,482 shares during the last quarter. Isthmus Partners LLC boosted its stake in Embecta by 4.8% during the fourth quarter. Isthmus Partners LLC now owns 138,729 shares of the company’s stock worth $1,648,000 after buying an additional 6,323 shares during the period. Swiss Life Asset Management Ltd bought a new position in Embecta during the fourth quarter valued at $145,000. Yacktman Asset Management LP raised its stake in shares of Embecta by 3.2% in the fourth quarter. Yacktman Asset Management LP now owns 2,262,915 shares of the company’s stock valued at $26,883,000 after acquiring an additional 71,209 shares during the period. Finally, Tweedy Browne Co LLC lifted its holdings in shares of Embecta by 16.7% in the 4th quarter. Tweedy Browne Co LLC now owns 48,191 shares of the company’s stock worth $573,000 after acquiring an additional 6,912 shares during the last quarter. 93.83% of the stock is owned by institutional investors.

Key Embecta News

Here are the key news stories impacting Embecta this week:

• Positive Sentiment: Q1 results beat expectations — EPS $0.71 vs. $0.67 consensus and revenue $261.2M vs. $258.1M; management provided slide deck and press release that highlight execution on core products. Embecta Q1 Results
• Positive Sentiment: BTIG reaffirmed a Buy and set a $25 price target (material upside vs. current levels), which can boost investor sentiment and momentum. BTIG Reaffirmation
• Positive Sentiment: Board declared a quarterly cash dividend of $0.15/share (annualized yield ~5.7%) — supports income-focused investors and may attract yield-seeking flows. Dividend Announcement
• Neutral Sentiment: Earnings call materials and transcripts are available (slides, call transcript, presentation) for investors wanting detail on product trends, margin drivers and regional performance; these provide transparency but no new catalyst by themselves. Earnings Presentation
• Negative Sentiment: FY2026 EPS guidance of $2.80–3.00 is modestly below sell‑side consensus (~$2.89), which could cap upside as investors weigh near-term growth headwinds vs. one-time execution positives. Guidance Details

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.